COSMO Pharmaceuticals SA (0RGI) - Cash Flow Conversion Efficiency
Based on the latest financial reports, COSMO Pharmaceuticals SA (0RGI) has a cash flow conversion efficiency ratio of 0.002x as of June 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (£900.00K ≈ $1.21 Million USD) by net assets (£466.98 Million ≈ $627.11 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See COSMO Pharmaceuticals SA (0RGI) balance sheet quality index to measure how much of total assets are equity-financed.
COSMO Pharmaceuticals SA - Cash Flow Conversion Efficiency Trend (2004–2024)
This chart illustrates how COSMO Pharmaceuticals SA's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check COSMO Pharmaceuticals SA cash flow quality index to evaluate the quality of earnings relative to operating cash generation.
COSMO Pharmaceuticals SA Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of COSMO Pharmaceuticals SA ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
North China Pharmaceutical Co Ltd
SHG:600812
|
0.025x |
|
WEIBO CORP. A
F:2WB
|
N/A |
|
Yapp Automotive Systems Co Ltd
SHG:603013
|
0.242x |
|
Palfinger AG
VI:PAL
|
0.004x |
|
Csg Smart Science&Technology Co Ltd
SHE:300222
|
0.084x |
|
Three's Company Media Group Co Ltd
SHG:605168
|
-0.021x |
|
Flow Traders BV
AS:FLOW
|
-1.463x |
|
Faraday Copper Corp.
TO:FDY
|
0.012x |
Annual Cash Flow Conversion Efficiency for COSMO Pharmaceuticals SA (2004–2024)
The table below shows the annual cash flow conversion efficiency of COSMO Pharmaceuticals SA from 2004 to 2024. For the full company profile with market capitalisation and key ratios, see market value of COSMO Pharmaceuticals SA.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | £505.09 Million ≈ $678.29 Million |
£162.41 Million ≈ $218.10 Million |
0.322x | +507.52% |
| 2023-12-31 | £429.04 Million ≈ $576.16 Million |
£22.71 Million ≈ $30.49 Million |
0.053x | -25.38% |
| 2022-12-31 | £463.79 Million ≈ $622.83 Million |
£32.89 Million ≈ $44.17 Million |
0.071x | +188.34% |
| 2021-12-31 | £512.68 Million ≈ $688.48 Million |
£12.61 Million ≈ $16.94 Million |
0.025x | -24.20% |
| 2020-12-31 | £400.12 Million ≈ $537.33 Million |
£12.98 Million ≈ $17.44 Million |
0.032x | +167.80% |
| 2019-12-31 | £393.73 Million ≈ $528.75 Million |
£-18.85 Million ≈ $-25.31 Million |
-0.048x | -109.50% |
| 2018-12-31 | £444.85 Million ≈ $597.40 Million |
£-10.16 Million ≈ $-13.65 Million |
-0.023x | -7.32% |
| 2017-12-31 | £470.12 Million ≈ $631.32 Million |
£-10.01 Million ≈ $-13.44 Million |
-0.021x | -133.50% |
| 2016-12-31 | £415.56 Million ≈ $558.06 Million |
£26.41 Million ≈ $35.47 Million |
0.064x | +165.40% |
| 2015-12-31 | £403.65 Million ≈ $542.06 Million |
£-39.23 Million ≈ $-52.68 Million |
-0.097x | -122.27% |
| 2014-12-31 | £152.29 Million ≈ $204.51 Million |
£66.45 Million ≈ $89.23 Million |
0.436x | +1084.01% |
| 2013-12-31 | £220.16 Million ≈ $295.65 Million |
£8.11 Million ≈ $10.90 Million |
0.037x | -80.04% |
| 2012-12-31 | £124.60 Million ≈ $167.33 Million |
£23.00 Million ≈ $30.89 Million |
0.185x | +3.72% |
| 2011-12-31 | £63.43 Million ≈ $85.19 Million |
£11.29 Million ≈ $15.16 Million |
0.178x | +33.42% |
| 2010-12-31 | £58.37 Million ≈ $78.38 Million |
£7.79 Million ≈ $10.46 Million |
0.133x | +105.80% |
| 2009-12-31 | £59.80 Million ≈ $80.30 Million |
£3.88 Million ≈ $5.21 Million |
0.065x | +122.39% |
| 2008-12-31 | £43.24 Million ≈ $58.06 Million |
£-12.52 Million ≈ $-16.81 Million |
-0.290x | -303.62% |
| 2007-12-31 | £35.15 Million ≈ $47.20 Million |
£-2.52 Million ≈ $-3.39 Million |
-0.072x | -106.31% |
| 2006-12-31 | £5.34 Million ≈ $7.18 Million |
£6.08 Million ≈ $8.16 Million |
1.137x | -57.78% |
| 2005-12-31 | £631.00K ≈ $847.38K |
£1.70 Million ≈ $2.28 Million |
2.694x | +1008.37% |
| 2004-12-31 | £-880.00K ≈ $-1.18 Million |
£261.00K ≈ $350.50K |
-0.297x | -- |
About COSMO Pharmaceuticals SA
Cosmo Pharmaceuticals N.V. focuses on the development and commercialization products for gastroenterology, dermatology, and healthtech worldwide. The company offers GI Genius, a computer-assisted system that uses artificial intelligence in real time to detect colorectal lesions; Winlevi, a prescription medicine used on the skin to treat acne vulgaris; Lialda/Mezavant/Mesavancol, a once-daily mesa… Read more